Facebook
Twitter
LinkedIn
ForwardNew Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment with Novel Therapeutics
In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients.
This activity can be accessed using the following URL: www.peerview.com/VVY
Target Audience
- Hematologists-Oncologists
- Medical Oncologists
- BMT Specialists
- BMT Nurse Specialists
- Other Clinician Involved in the Management of GVHD
Learning Objectives
| • | Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD |
| • | Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting |
| • | Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics |
Support Statement
This activity is supported by educational grants from CSL Behring, Incyte Corporation, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Co-Chairs & Presenters
Corey Cutler, MD, MPH, FRCP(C)
Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Corey Cutler, MD, MPH, FRCP(C), has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Generon; Genzyme Corporation; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Omeros Corporation; and Syndax.
Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplantation Service
Associate Member
Memorial Sloan Kettering Cancer Center
New York, New York
Miguel-Angel Perales, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Astellas Pharma Inc.; Bellicum Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Incyte Corporation; Kite Pharma/Gilead Sciences, Inc.; Merck & Co., Inc.; Miltenyi Biotec; Nektar; Novartis Pharmaceuticals Corporation; Omeros Corporation; and Takeda Pharmaceutical Company Limited.
Data Safety Monitoring Board for Cidara Therapeutics, Inc.; Medigene AG; and Servier Pharmaceuticals LLC.
Other Financial or Material Support from Neximmune as a Scientific Advisory Board (SAB) member.
CME Reviewers
Anita D’Souza, MD
Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.
Bronwen E. Shaw, MD, PhD
Bronwen E. Shaw, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Orca Bio and Therakos.
Other Financial or Material Support CIBMTR receives financial support from the government, foundations and industry entities to support broad research and educational missions. These funding sources are disclosed for transparency. Scientific and administrative review processes prevent direct influence of the funding sources to the CIBMTR scientific research agenda and individual research products and findings.
Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.